However, we found that treatment with RUX alone, and in combination with PAC, decreased the frequency of intratumoral GZMB+CD8+ and GZMB+CD4+ cells, which suggests a switch to a less active, tumor-promoting immune environment. The gene discussed is CD8A; the disease is neoplasm.